FI3250182T3 - Dispergoituvia koostumuksia - Google Patents
Dispergoituvia koostumuksia Download PDFInfo
- Publication number
- FI3250182T3 FI3250182T3 FIEP16701516.3T FI16701516T FI3250182T3 FI 3250182 T3 FI3250182 T3 FI 3250182T3 FI 16701516 T FI16701516 T FI 16701516T FI 3250182 T3 FI3250182 T3 FI 3250182T3
- Authority
- FI
- Finland
- Prior art keywords
- fraction
- intragranular
- tablet
- diluent
- extragranular
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 20
- 239000003085 diluting agent Substances 0.000 claims 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims 16
- 239000011230 binding agent Substances 0.000 claims 14
- 239000007916 tablet composition Substances 0.000 claims 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 11
- 239000000314 lubricant Substances 0.000 claims 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 8
- 229960000913 crospovidone Drugs 0.000 claims 8
- 239000007884 disintegrant Substances 0.000 claims 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 6
- 239000000377 silicon dioxide Substances 0.000 claims 6
- 229960001137 bedaquiline fumarate Drugs 0.000 claims 5
- ZLVSPMRFRHMMOY-WWCCMVHESA-N bedaquiline fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 ZLVSPMRFRHMMOY-WWCCMVHESA-N 0.000 claims 5
- 239000008119 colloidal silica Substances 0.000 claims 5
- 201000008827 tuberculosis Diseases 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229960003943 hypromellose Drugs 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 4
- 229940068977 polysorbate 20 Drugs 0.000 claims 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000000080 wetting agent Substances 0.000 claims 4
- 229960000508 bedaquiline Drugs 0.000 claims 3
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Lubricants (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN264MU2015 | 2015-01-27 | ||
| PCT/EP2016/051545 WO2016120258A1 (fr) | 2015-01-27 | 2016-01-26 | Compositions dispersibles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3250182T3 true FI3250182T3 (fi) | 2023-06-28 |
Family
ID=55229712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16701516.3T FI3250182T3 (fi) | 2015-01-27 | 2016-01-26 | Dispergoituvia koostumuksia |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20180000810A1 (fr) |
| EP (1) | EP3250182B1 (fr) |
| JP (3) | JP7291458B2 (fr) |
| KR (1) | KR102631986B1 (fr) |
| CN (2) | CN114129526A (fr) |
| AU (2) | AU2016212116B2 (fr) |
| CA (1) | CA2973301A1 (fr) |
| CY (1) | CY1126107T1 (fr) |
| DK (1) | DK3250182T3 (fr) |
| EA (1) | EA201791701A1 (fr) |
| ES (1) | ES2948805T3 (fr) |
| FI (1) | FI3250182T3 (fr) |
| HK (1) | HK1243644A1 (fr) |
| HR (1) | HRP20230616T1 (fr) |
| HU (1) | HUE062481T2 (fr) |
| IL (2) | IL310920A (fr) |
| LT (1) | LT3250182T (fr) |
| MA (1) | MA41411B1 (fr) |
| MD (1) | MD3250182T2 (fr) |
| MX (1) | MX2017009681A (fr) |
| PE (1) | PE20171319A1 (fr) |
| PH (1) | PH12017501331A1 (fr) |
| PL (1) | PL3250182T3 (fr) |
| PT (1) | PT3250182T (fr) |
| RS (1) | RS64308B1 (fr) |
| SG (1) | SG11201705944TA (fr) |
| SI (1) | SI3250182T1 (fr) |
| UA (1) | UA126891C2 (fr) |
| WO (1) | WO2016120258A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2937365C (fr) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee |
| ES2891976T3 (es) * | 2017-07-14 | 2022-02-01 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo |
| WO2019193609A1 (fr) * | 2018-04-05 | 2019-10-10 | Cipla Limited | Formulations pharmaceutiques |
| US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
| WO2020123336A1 (fr) * | 2018-12-13 | 2020-06-18 | Qrumpharma Inc. | Compositions de bédaquiline, combinaisons les comprenant, leurs procédés de préparation, utilisations et procédés les comprenant |
| KR20210113628A (ko) * | 2019-01-09 | 2021-09-16 | 얀센 파마슈티카 엔.브이. | 비결핵성 마이코박테리아 질환의 치료에서의 조합물 |
| CN111888477B (zh) * | 2020-09-15 | 2023-03-07 | 北京福元医药股份有限公司 | 一种贝达喹啉药物制剂 |
| KR102478006B1 (ko) | 2020-12-03 | 2022-12-15 | 정승찬 | 자동차 긴급 제동장치 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| GB202211231D0 (en) | 2022-08-02 | 2022-09-14 | Glaxosmithkline Ip No 2 Ltd | Novel formulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2421A (en) | 2002-07-25 | 2012-06-08 | Janssen Pharmaceutica Nl | Quinoline derivatives and their use as mycobacterial inhibitors. |
| EA010651B1 (ru) | 2004-05-28 | 2008-10-30 | Янссен Фармацевтика Н.В. | Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам |
| EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| NZ563819A (en) * | 2005-05-25 | 2011-01-28 | Janssen Pharmaceutica Nv | Process for preparing (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-napthalenyl-beta-phenyl-3-quinolineethanol (R207910) |
| EE05697B1 (et) * | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
| AU2007283196A1 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition |
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| US20110159084A1 (en) * | 2008-04-02 | 2011-06-30 | Dr. Reddy's Laboratories Ltd. | Raloxifene pharmaceutical formulations |
| CN102143748A (zh) * | 2008-09-03 | 2011-08-03 | 辉瑞大药厂 | 用于肺结核的联合疗法 |
| US20120207838A1 (en) * | 2011-02-10 | 2012-08-16 | Perricone Nicholas V | Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps |
| WO2013153162A1 (fr) * | 2012-04-11 | 2013-10-17 | Sandoz Ag | Polymorphe de chlorhydrate de rilpivirine |
| US20140075692A1 (en) * | 2012-09-18 | 2014-03-20 | Unger Marketing International, Llc. | Multiuse cleaning tool handle |
| MX2015006217A (es) * | 2012-11-19 | 2015-11-16 | Azanta As | Tableta dispersable. |
-
2016
- 2016-01-26 IL IL310920A patent/IL310920A/en unknown
- 2016-01-26 RS RS20230495A patent/RS64308B1/sr unknown
- 2016-01-26 MX MX2017009681A patent/MX2017009681A/es unknown
- 2016-01-26 ES ES16701516T patent/ES2948805T3/es active Active
- 2016-01-26 EP EP16701516.3A patent/EP3250182B1/fr active Active
- 2016-01-26 CA CA2973301A patent/CA2973301A1/fr active Pending
- 2016-01-26 PE PE2017001255A patent/PE20171319A1/es unknown
- 2016-01-26 US US15/545,524 patent/US20180000810A1/en not_active Abandoned
- 2016-01-26 WO PCT/EP2016/051545 patent/WO2016120258A1/fr active Application Filing
- 2016-01-26 UA UAA201708632A patent/UA126891C2/uk unknown
- 2016-01-26 DK DK16701516.3T patent/DK3250182T3/da active
- 2016-01-26 CN CN202111218462.7A patent/CN114129526A/zh active Pending
- 2016-01-26 PL PL16701516.3T patent/PL3250182T3/pl unknown
- 2016-01-26 KR KR1020177023308A patent/KR102631986B1/ko active IP Right Grant
- 2016-01-26 CN CN201680007314.1A patent/CN107205945A/zh active Pending
- 2016-01-26 JP JP2017557493A patent/JP7291458B2/ja active Active
- 2016-01-26 IL IL253626A patent/IL253626B1/en unknown
- 2016-01-26 MD MDE20170303T patent/MD3250182T2/ro unknown
- 2016-01-26 LT LTEPPCT/EP2016/051545T patent/LT3250182T/lt unknown
- 2016-01-26 SG SG11201705944TA patent/SG11201705944TA/en unknown
- 2016-01-26 MA MA41411A patent/MA41411B1/fr unknown
- 2016-01-26 HU HUE16701516A patent/HUE062481T2/hu unknown
- 2016-01-26 AU AU2016212116A patent/AU2016212116B2/en active Active
- 2016-01-26 HR HRP20230616TT patent/HRP20230616T1/hr unknown
- 2016-01-26 PT PT167015163T patent/PT3250182T/pt unknown
- 2016-01-26 SI SI201631721T patent/SI3250182T1/sl unknown
- 2016-01-26 EA EA201791701A patent/EA201791701A1/ru unknown
- 2016-01-26 FI FIEP16701516.3T patent/FI3250182T3/fi active
-
2017
- 2017-07-21 PH PH12017501331A patent/PH12017501331A1/en unknown
-
2018
- 2018-03-08 HK HK18103261.6A patent/HK1243644A1/zh unknown
-
2021
- 2021-02-12 JP JP2021020595A patent/JP2021098706A/ja active Pending
- 2021-06-21 AU AU2021204135A patent/AU2021204135B2/en active Active
-
2022
- 2022-02-03 US US17/592,097 patent/US20220331307A1/en not_active Abandoned
- 2022-08-22 JP JP2022131578A patent/JP2022176982A/ja active Pending
-
2023
- 2023-07-07 CY CY20231100319T patent/CY1126107T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3250182T3 (fi) | Dispergoituvia koostumuksia | |
| HRP20200138T1 (hr) | Kombinirana formulacija dva antivirusna spoja | |
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| JP2006104221A5 (fr) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| ECSP024401A (es) | Procedimiento para preparar una composicion | |
| HRP20192026T4 (hr) | Formulacija tableta od neratinib maleata | |
| AR079930A2 (es) | Formulaciones de inhibidores de dipeptidil peptidasa iv (dpp iv) | |
| WO2015148415A3 (fr) | Utilisation de la plate-forme structurale chimique centrale de fl118 pour produire des dérivés de fl118 pour le traitement d'une maladie humaine | |
| WO2018042362A9 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MX2021010359A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| HRP20230559T1 (hr) | Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja | |
| NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
| WO2008110585A3 (fr) | Compositions et procédés pour prévenir et traiter l'inflammation d'une muqueuse et la perte de poids | |
| DK2170857T3 (da) | 3',4',5-trimethoxyflavonderivater som stimulerende middel ved slimafsondring, tilsvarende fremgangsmåde og farmaceutisk præparat, der indeholder disse | |
| WO2017182873A3 (fr) | Composés foldamères de peptide-oligourée et leurs procédés d'utilisation | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| JP2016505016A5 (fr) | ||
| EP3852760A4 (fr) | Matière de composition, synthèse, formulation et application d'analogues dérivés en positions 9 et 7 sur la plate-forme fl118 pour le traitement d'une maladie humaine | |
| CA2835272A1 (fr) | Composition pharmaceutique antiretrovirale | |
| AR097512A1 (es) | Forma de dosis unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir | |
| MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
| WO2005120518A3 (fr) | Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires |